Novo Nordisk’s new weight-loss drug helped patients lose even more weight on average than its current Wegovy blockbuster treatment, an early-stage trial showed, as the drugmaker races to develop the next generation of obesity medicines.

Novo Nordisk is seen as having fallen behind in the race for new obesity drugs. It argues it is playing the long game.

Novo Nordisk (NYSE:NVO) is one of the most active stocks to buy according to analysts. On June 20, Novo Nordisk announced that its investigational obesity treatment, amycretin, will advance directly to Phase 3 clinical development.